# Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine

> **NCT01696422** · PHASE2 · UNKNOWN · sponsor: **Butantan Institute** · enrollment: 300 (actual)

## Conditions studied

- Dengue

## Interventions

- **BIOLOGICAL:** Dengue 1,2,3,4 (attenuated) vaccine
- **BIOLOGICAL:** TetraVax-DV Vaccine - Admixture TV003
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01696422
- **Lead sponsor:** Butantan Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-10
- **Primary completion:** 2016-04
- **Final completion:** 2020-12
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2019-01-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01696422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01696422, "Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01696422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*